Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

drug-induced localized lipodystrophy - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

drug-induced localized lipodystrophy

MONDO:0019553

Also known as:lipoatrophy caused by injected drug

Overview

Drug-induced localized lipodystrophy is a rare, acquired, localized lipodystrophy characterized by the appearance of asymptomatic, well-demarcated, variably sized, depressed, lipoatrophic lesions secondary to subcutaneous, intradermic or intramuscular drug injection, including corticosteroids, insulin, human growth hormone and antibiotics. Skin coloration may vary from white or hypopigmented to reddish, pinkish or violaceous. Epidermal atrophy may be also present.

ResearchLimited published research (7 articles)

Prognosis

Estimated prevalence: <1 in 1,000,000 (VERY_RARE).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for drug-induced localized lipodystrophy.

7 publications have been identified in PubMed for drug-induced localized lipodystrophy. Research spans Case Report / Case Series (43%), Epidemiology / Natural History (29%), and Review / Meta-Analysis (14%).

Recent Publications

Oi Y (2025). [PMID: 40368784](https://pubmed.ncbi.nlm.nih.gov/40368784/). *Internal medicine (Tokyo, Japan)*. [Case Report / Case Series]
Stukey GJ (2025). [PMID: 39577771](https://pubmed.ncbi.nlm.nih.gov/39577771/). *Journal of lipid research*. [Basic Science / Preclinical]
Kruglikov IL (2025). [PMID: 41316800](https://pubmed.ncbi.nlm.nih.gov/41316800/). *Journal of cosmetic dermatology*. [Case Report / Case Series]
Rakusa M (2024). [PMID: 39120809](https://pubmed.ncbi.nlm.nih.gov/39120809/). *Pituitary*. [Epidemiology / Natural History]
Raynor WY (2024). [PMID: 39004664](https://pubmed.ncbi.nlm.nih.gov/39004664/). *EJNMMI reports*. [Review / Meta-Analysis]

Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 11:31 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:90157

GARD

Genetic and Rare Diseases Info Center

GARD:19126

Questions for Your Care Team

→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

drug-induced localized lipodystrophy

Overview

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team